Treatment of acute bacterial skin and skin structure infections (ABSSSI).
Inhibits bacterial protein synthesis at the level of the 23S ribosome of the 50S subunit.
Bacteriostatic action against enterococci, staphylococci and streptococci, resulting is resolution of infection.Spectrum:
Active against Staphylococcus aureus including methicillin-resistant strains (MRSA), Streptococcus pyogens, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, Streptococcus constellatus) and Enterococcus faecalis.
Absorption: IV administration results in complete bioavailability; well absorbed (91%) following oral administration, rapidly converted by phosphatases to its active form.
Distribution: Penetrates interstitial fluid space of adipose and skeletal muscle resulting in similar levels to plasma.
Metabolism and Excretion: Eliminated via liver with inactive metabolites excreted in feces (82%) and urine (18%); <3% excreted unchanged in urine or feces.
Half-life: 12 hr.
TIME/ACTION PROFILE (blood levels)
|PO||unknown||2.5 hr||24 hr|
|IV||rapid||end of infusion||24 hr|
- Uncontrolled HTN, pheochromocytoma, thyrotoxicosis, or concurrent use of sympathomimetic agents, vasopressors, or dopaminergic agents (↑ risk of hypertensive response);
- Concurrent or recent (<2 wk) use of monoamine oxidase (MAO) inhibitors (↑ risk of hypertensive response);
- Carcinoid syndrome or concurrent use of SSRIs, TCAs, triptans, meperidine, or buspirone (↑ risk of serotonin syndrome).
Use Cautiously in:
- Neutropenia (safety and efficacy not established if WBC <1000 cells/mm3 )
- OB: Use in pregnancy only in potential maternal benefit justifies potential risk to fetus;
- Lactation:Use cautiously if breast feeding;
- Pedi: Safe and effective use in children <18 yr has not been established.
Adverse Reactions/Side Effects
CNS: dizziness, headache
GI: CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA (CDAD), nausea, diarrhea, vomiting
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
- ↑ risk of hypertensive response with MAO inhibitors, sympathomimetics (e.g., pseudoephedrine ), vasopressors (e.g., epinephrine, norepinephrine ), and dopaminergic agents (e.g., dopamine, dobutamine); concurrent or recent use should be avoided.
- ↑ risk of serotonin syndrome with SSRIs, TCAs, triptans, meperidine, bupropion, or buspirone; avoid concurrent use.
- May ↑ levels of methotrexate, topotecan, or rosuvastatin; discontinue these medications temporarily during tedizolid treatment.
PO: IV: (Adults) 200 mg once daily for six days.
Tablets: 200 mg
Lyophilized powder for injection: 200 mg/vial
- Assess for infection (vital signs; appearance of wound, sputum, urine, and stool; WBC) at beginning of and during therapy.
- Obtain specimens for culture and sensitivity prior to initiating therapy. First dose may be given before receiving.
- Monitor bowel function. Diarrhea, abdominal cramping, fever, and bloody stools should be reported to health care professional promptly as a sign of Clostridium difficile-associated diarrhea (CDAD). May begin up to several mo following cessation of therapy.
Lab Test Considerations:
Consider alternate therapies in patients with neutrophil counts <1000 cells/mm3 .
- May cause anemia.
- Dose adjustment is not necessary when switching from IV to oral dose.
- PO: May be administered with or without food.
- Intermittent Infusion: Reconstitute each vial with 4 mL of Sterile Water for Injection. Gently swirl and let vial stand until completely dissolved; avoid shaking. Diluent: Dilute further with 250 mL of 0.9% NaCl by slowing injecting reconstituted solution into 250 mL bag. Gently invert bag to mix; avoid shaking to minimize foaming. Solution is clear and colorless to pale yellow; do not administer solutions that are discolored or contain particulate material. Must be used within 24 hrs of reconstitution at room temperature or under refrigeration.
- Rate: Infuse over 1 hr.
- Y-Site Incompatibility
- solutions containing calcium or magnesium
- Lactated Ringer's
- Hartmann's solution
- Advise patients taking oral tedizolid to take as directed, for full course of therapy, even if feeling better. Take missed doses as soon as remembered up to 8 hrs before next dose; if less than 8 hrs before next dose, wait until next scheduled dose. Do not double dose.
- Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
- Instruct patient to notify health care professional if changes in vision occur or immediately if diarrhea, abdominal cramping, fever, or bloody stools occur and not to treat with antidiarrheals without consulting health care professionals.
- Advise female patient to notify health care professional if pregnancy is planned or suspected or if breast feeding.
- Advise patient to notify health care professional if no improvement is seen in a few days.
Resolution of signs and symptoms of infection. Length of time for complete resolution depends on organism and site of infection.
Nursing Central is the award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Learn more.